Associate Director, Regulatory Affairs (CMC)
Arrowhead Pharmaceuticals
Summary
The Associate Director, CMC Regulatory Affairs ensures efficient and compliant management of regulatory change control and post-approval activities. Supporting diverse modalities including small molecules, biologics, and external manufacturing sites, the role employs an agile approach to drive standardization, scalability, and sustainability.
Job description
The Position
The Associate Director, CMC Regulatory Affairs ensures efficient and compliant management of regulatory change control and post-approval activities. Supporting diverse modalities including small molecules, biologics, and external manufacturing sites, the role employs an agile approach to drive standardization, scalability, and sustainability.
This position leverages ICH Q12 principles to streamline post-approval change management. The Associate Director will have good experience with global HA requirements along with an understanding of scientific principles and regulatory CMC requirements relevant to global drug development and post-market support.
Responsibilities
- Lead post-approval change management activities, including record evaluations and regulatory submissions (considering possible strategic bundling of changes), ensuring compliance with global requirements.
- Apply science- and risk-based approaches, guided by ICH Q12 principles, to assess and implement post-approval changes.
- Explore and implement automation technologies to increase efficiency and ensure repeatability in change control and regulatory submissions.
- Provide centralized regulatory support for manufacturing sites, including external partners, covering small molecules and biologics.
- Collaborate with external manufacturing sites and suppliers to align change control processes with global regulatory expectations.
- Ensure site compliance with global regulatory requirements by evaluating and prioritizing changes based on risk and scientific rationale.
- Facilitate alignment between CMC teams and global Regulatory CMC on post-approval strategies and activities and represent global Regulatory CMC in cross-functional Change Review meetings.
- Implement streamlined workflows for regulatory change control, leveraging digital tools and automation to minimize delays and maximize impact.
Requirements
- BS/BA Degree in a Scientific Discipline
- Experience with CMC Life Cycle Management Systems (such as Veeva Registrations)
- 12+ years of overall biopharmaceutical/device industry experience with 8+ years of direct Regulatory CMC experience required
- Strong practical experience with global HA requirements
- Understanding of scientific principles and regulatory CMC requirements relevant to global drug development and post-market support
- Proven ability to understand and communicate regulatory strategy to drug development, registration, and post-market support teams
- Proven ability to develop global regulatory strategy recommendations based on precedents and other regulatory intelligence as well as regulations and guidelines
- Able to deal with issues of critical importance with minimal oversight
Preferred
- Advanced Degree (M.S., Ph.D., etc.)
Requirements
- BS/BA Degree in a Scientific Discipline
- Experience with CMC Life Cycle Management Systems (such as Veeva Registrations)
- 12+ years of overall biopharmaceutical/device industry experience
- 8+ years of direct Regulatory CMC experience
- Strong practical experience with global HA requirements
- Understanding of scientific principles and regulatory CMC requirements relevant to global drug development and post-market support
- Proven ability to understand and communicate regulatory strategy to drug development, registration, and post-market support teams
- Proven ability to develop global regulatory strategy recommendations based on precedents and regulatory intelligence
- Able to deal with issues of critical importance with minimal oversight
- Advanced Degree (M.S., Ph.D., etc.) preferred
Benefits
- Competitive Salaries
- Excellent Benefit Package
Company overview
Arrowhead Pharmaceuticals, Inc. is a publicly traded biotechnology company headquartered in Pasadena, California, specializing in the development of gene silencing therapeutics through RNA interference (RNAi) technology. Founded in 2004 and listed on Nasdaq under the ticker ARWR, the company focuses on treating intractable diseases by silencing disease-causing genes. Arrowhead's innovative TRiM (Targeted RNAi Molecule) platform enables precise targeting of specific messenger RNAs to reduce production of proteins associated with various conditions. The company's pipeline includes treatments for hepatitis B, liver diseases associated with alpha 1-antitrypsin deficiency, cardiovascular diseases, hypertriglyceridemia, and other metabolic disorders. With approximately 609 employees, Arrowhead has established significant partnerships with major pharmaceutical companies including Janssen, Amgen, and Takeda, demonstrating the commercial potential of its RNAi platform. The company recently achieved FDA approval for its therapy targeting Familial Chylomicronemia Syndrome (FCS), marking a significant milestone in its mission to revolutionize treatment approaches for challenging diseases.